Table 6.
Name | Percent selected | Coefficient | |||
---|---|---|---|---|---|
Median | 99% CI | 95% CI | |||
(Intercept) | 100 | – 5.10E+00 | (− 6.03, − 3.92) | (− 6.31, − 3.57) | |
Tocilizumab:Mechanical_Ventilation | 56.3 | – 5.00E– 01 | (− 1.59, − 0.0213) | (− 1.94, − 4.06e–03) | |
Gender:Neoplastic_Disease | 61.7 | – 4.87E– 01 | (− 1.69, − 0.0274) | (− 2.1, − 4.98e–03) | |
Ondansetron:Mechanical_Ventilation | 74.4 | – 3.65E– 01 | (− 1.14, − 0.0201) | (− 1.38, − 4.51e–03) | |
Age:Ferritin | 55.3 | 3.47E– 07 | (2.60e–09, 1.22e–06) | (2.06e–08, 9.57e–07) | |
CRP:BUN | 68 | 2.80E– 05 | (2.03e–07, 1.17e–04) | (1.42e–06, 9.15e–05) | |
Age^2 | 99.1 | 2.68E– 04 | (3.25e–05, 5.00e–04) | (7.95e–05, 4.42e–04) | |
Age:Remdesivir | 75.9 | 3.67E– 03 | (3.75e–05, 1.68e–02) | (2.36e–04, 1.29e–02) | |
BUN | 52.9 | 7.39E– 03 | (2.95e–05, 2.23e–02) | (2.27e–04, 1.84e–02) | |
Gender:Dimer | 60.6 | 2.37E– 02 | (1.70e–04, 8.38e–02) | (1.09e–03, 6.79e–02) | |
Gender:Mechanical_Ventilation | 61.4 | 2.30E– 01 | (1.34e–03, 9.10e–01) | (9.56e–03, 7.19e–01) | |
COPD:Mechanical_Ventilation | 51.3 | 2.64E– 01 | (− 1.36e–01, 1.25e+00) | (7.95e–03, 9.44e–01) | |
Ondansetron:Convalescent_plasma | 52.9 | 4.56E– 01 | (2.94e–03, 1.69e+00) | (2.33e–02, 1.34e+00) | |
Mechanical_Ventilation | 99.8 | 2.54E+00 | (4.73e–01, 3.76e+00) | (1.07e+00, 3.41e+00) |
Covariates are sorted by the median value of their coefficients, along with their 95% and 99% Cis
Age approximate age of patient (one of 35, 45,…, 75 years), BUN blood urea nitrogen, CI confidence interval, COPD chronic obstructive pulmonary disease, CRP C-reactive protein, : indicates interaction between two covariates
Negative median sign means association with decreased mortality (bold)